CXCR4/STAT3在骨髓基质细胞介导的急性髓系白血病耐药中的作用研究

OBJECTIVE: To explore the role of CXCR4/STAT3 in mesenchymal stromal cell (MSC)-mediated drug resistance of AML cells. METHODS: AML cell lines U937 and KG1a and primary AML cells were co-cultured with MSC from bone marrow of healthy donors. The AML cell lines cultured alone were used as control. Apoptosis induced by mitoxantrone was measured by flow cytometry. Expression of CXCR4 and STAT3 protein were detected by Western blot. After incubated with STAT3 inhibitor Cucurbitacin Ⅰ or CXCR4 antagonist AMD3100, the apoptosis of AML cells induced by mitoxantrone was evaluated. RESULTS: Apoptosis of AML cells (U937 and KG1a) and primary AML cells induced by mitoxantrone significantly decreasedin cocultured group than that of control group [U937 cells: (20.08±1.53)% vs (45.33 ± 1.03)%, P=0.004; KG1a cells: (25.60 ± 1.82)% vs (40.33 ± 3.29)%, P=0.020]. Expression of phosphorylated STAT3 and CXCR4 protein in AML cells were upregulated in cocultured group. After addition of Cucurbitacin Ⅰ into the co-culture system, the apoptosis rate of primary AML cells significantly increased. Similar results of the apoptosis rates were also detected when the inhibitor of CXCR4 AMD3100 was added to overcome the stromal cell-mediated drug resistance. Besides, the expression of p-STAT3 in AML cells after incubated with AMD3100 decreased significantly. CONCLUSION: AML cells cocultured with MSC leads to the up-regulation of phosphorylated STAT3 and CXCR4 proteins, which resulted in AML cells resistance to chemotherapeutic drugs. Therefore targeting STAT3 or CXCR4 could be a new therapeutic strategy of AML.